Date: 2015-11-07
Type of information: Presentation of results at a congress
phase: 1
Announcement: presentation of results at the 2015 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Company: Macrogenics (USA - MD)
Product: enoblituzumab (MGA271)
Action
mechanism: monoclonal antibody. Enoblituzumab is a humanized, Fc-optimized monoclonal antibody that targets B7-H3, a member of the B7 family of molecules that are involved in immune regulation. B7-H3 is over-expressed by a wide variety of solid tumor cells as well as cancer stem cells and tumor-associated vasculature.
Disease: cancers expressing B7-H3 in the tumor and/or tumor-associated vasculature
Therapeutic area: Cancer - Oncology
Country:
Trial details:
Latest
news: * On November 7, 2015, MacroGenics announced that interim results of an ongoing Phase 1 dose-escalation study of enoblituzumab (MGA271) were presented in the late-breaking abstract session at the 2015 Society for Immunotherapy of Cancer (SITC) Annual Meeting in National Harbor , MD. Dr. John Powderly II of the Carolina BioOncology Institute , Huntersville, NC , presented "Interim Results of an Ongoing Phase 1, Dose Escalation Study of MGA271 (Fc-optimized Humanized Anti-B7-H3 Monoclonal Antibody) in Patients with Refractory B7-H3-Expressing Neoplasms or Neoplasms Whose Vasculature Expresses B7-H3." This study is being conducted to evaluate the safety of enoblituzumab in patients with advanced cancer that expresses B7-H3 in the tumor and/or tumor-associated vasculature. Additional study objectives are to define the toxicity profile, maximum tolerated dose, pharmacokinetics, immunogenicity and potential anti-tumor activity of enoblituzumab in patients with refractory cancer that expresses B7-H3. Enoblituzumab has been well tolerated at all dose levels tested in the Phase 1 study (up to 15 mg/kg), with Grade 3/Grade 4 drug-related adverse events (AEs) in only 4% of patients, no severe immune-related adverse events, and no drug-related treatment discontinuations. The most common AEs have been infusion-related reactions and fatigue. Mild-moderate infusion reactions have been readily managed with conventional supportive care, including administration of corticosteroids and a decreased infusion rate. In this ongoing Phase 1 dose-escalation study of enoblituzumab, monotherapy anti-tumor activity was observed across several tumor types, including patients with prostate and bladder cancer as well as melanoma. Overall, this patient population had been heavily pre-treated (median number of prior therapies = 3), and in the patients with melanoma, all had been treated previously with one or more checkpoint inhibitors (anti-CTLA-4, anti-PD-1 and/or anti-PD-L1 antibodies). In addition to the presentation of initial safety and activity data, Dr. Powderly presented findings demonstrating increases in T-cell repertoire (TCR) clonality in the peripheral blood of tumor patients following treatment with enoblituzumab, demonstrating that enoblituzumab can modulate T cells in these patients. Collectively, these findings support the ongoing evaluation of enoblituzumab as monotherapy and in combination with other immuno-oncology agents, including pembrolizumab and ipilimumab. MacroGenics plans to present additional clinical data in 2016, as it continues to enroll patients in additional monotherapy expansion cohorts and recently commenced two combination studies of enoblituzumab with either ipilimumab or pembrolizumab.
